ALLR news

Allarity received recent patent awards and CLIA certification to retain exclusive control of its Drug Response Predictor test for stenoparib, aiding its clinical development strategy.

Allarity Therapeutics announced the grant of a Japanese Patent (7917283) for its stenoparib Drug Response Predictor (DRP) companion diagnostic, extending patent protection through 2039 in Japan. The patent covers methods to predict clinical benefit from the drug, reinforcing the company's intellectu…

Allarity Acquisition Corp. announced it filed a Form S-1 for a $100 million initial public offering to pursue a business combination. Market remains neutral on this corporate separation.

Allarity Therapeutics announced the USPTO has granted a key patent covering its stenoparib DRP companion diagnostic. This milestone secures exclusivity for stenoparib until 2042, validating the company's strategy for precision oncology and supporting FDA approval efforts.

Allarity Therapeutics will present a Trial-in-Progress poster on its Phase 2 stenoparib study for platinum-resistant ovarian cancer at the ESMO Gynaecological Cancers Congress in Copenhagen. The presentation showcases the clinical rationale for the dual PARP and WNT pathway inhibitor ahead of upcomi…